# Immunoexpression of Survivin and P53 in the Histological Subtypes of Medulloblastoma: A Cross-Sectional Observational Study

## TL;DR

This study examines the presence of Survivin and P53 proteins in different types of medulloblastoma tumors to explore their potential role in prognosis and treatment.

## Contribution

The study identifies Survivin and P53 immunoreactivity patterns in medulloblastoma subtypes, suggesting their potential as prognostic markers.

## Key findings

- Survivin was expressed in 75% of medulloblastoma cases, primarily in the cytoplasm.
- p53 nuclear expression was observed in 35% of cases, with classical variant tumors showing predominant p53 and cytoplasmic Survivin expression.
- The association of Survivin and p53 with poor prognosis suggests potential for targeted therapies.

## Abstract

Medulloblastoma (MB) is a common malignant intracranial neoplasms in children. The treatment and prognosis of this tumor depends on histology and molecular subtypes. Survivin, implicated in various malignancies, may hold prognostic significance. We investigated survivin and p53 immunoreactivity in different histological subtypes in 20 MB cases from January 2018 to June 2021. Immunohistochemistry revealed survivin expression in 75% (15/20) of cases, with cytoplasmic (10 cases), nuclear (four cases), or combined expression (one case). p53 nuclear expression was present in 35% (7/20) of cases. Classical variant MB exhibited predominant p53 and cytoplasmic survivin expression. Given the association of survivin and p53 expression with poor prognosis, especially in the prevalent classical variant, targeted therapies may hold promise for MB treatment advancement.